enGene Therapeutics Inc. Basic Shares Outstanding (Weighted Average)
enGene Therapeutics Inc. (ENGN) reported Basic Shares Outstanding (Weighted Average) of 69.73 million shares for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-08.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-09-08
- enGene Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-07-31 was 69.73M shares, a 36.47% increase year-over-year.
- enGene Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-04-30 was 69.72M shares, a 36.66% increase year-over-year.
- enGene Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-01-31 was 67.26M shares, a 31.95% increase year-over-year.
- enGene Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-10-31 was 51.38M shares, a 15.64% increase year-over-year.
- enGene Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 51.12M shares, a 35.30% increase from fiscal 2024.
- enGene Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 37.78M shares, a 5355.08% increase from fiscal 2023.
- enGene Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 692.61K shares, a 5.72% increase from fiscal 2022.
- enGene Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 655.15K shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-07-31 | 69.73M shares 10-Q · filed 2026-09-08 | 69.73M shares derived: average of 2 quarters · filed 2026-09-08 | 68.90M shares 10-Q · filed 2026-09-08 | 64.53M shares derived: average of 4 quarters · filed 2026-09-08 |
| 2026-04-30 | 69.72M shares 10-Q · filed 2026-06-15 | 68.47M shares 10-Q · filed 2026-06-15 | 62.79M shares derived: average of 3 quarters · filed 2026-06-15 | 59.87M shares derived: average of 4 quarters · filed 2026-09-08 |
| 2026-01-31 | 67.26M shares 10-Q · filed 2026-03-09 | 59.32M shares derived: average of 2 quarters · filed 2026-03-09 | 56.58M shares derived: average of 3 quarters · filed 2026-09-08 | 55.19M shares derived: average of 4 quarters · filed 2026-09-08 |
| 2025-10-31 | 51.38M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | 51.24M shares derived: average of 2 quarters · filed 2026-09-08 | 51.17M shares derived: average of 3 quarters · filed 2026-09-08 | 51.12M shares 10-K · filed 2025-12-22 |
| 2025-07-31 | 51.10M shares 10-Q · filed 2026-09-08 | 51.06M shares derived: average of 2 quarters · filed 2026-09-08 | 51.03M shares 10-Q · filed 2026-09-08 | 49.38M shares derived: average of 4 quarters · filed 2026-09-08 |
| 2025-04-30 | 51.02M shares 10-Q · filed 2026-06-15 | 51.00M shares 10-Q · filed 2026-06-15 | 48.81M shares derived: average of 3 quarters · filed 2026-06-15 | 47.65M shares derived: average of 4 quarters · filed 2026-06-15 |
| 2025-01-31 | 50.98M shares 10-Q · filed 2026-03-09 | 47.71M shares derived: average of 2 quarters · filed 2026-03-09 | 46.53M shares derived: average of 3 quarters · filed 2026-03-09 | 44.76M shares derived: average of 4 quarters · filed 2026-03-09 |
| 2024-10-31 | 44.44M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-22 | 44.30M shares derived: average of 2 quarters · filed 2025-12-22 | 42.68M shares derived: average of 3 quarters · filed 2025-12-22 | 37.78M shares 10-K · filed 2025-12-22 |
| 2024-07-31 | 44.17M shares 10-Q · filed 2025-09-11 | 41.81M shares derived: average of 2 quarters · filed 2025-09-11 | 35.56M shares 10-Q · filed 2025-09-11 | 26.88M shares derived: average of 4 quarters · filed 2025-09-11 |
| 2024-04-30 | 39.44M shares 10-Q · filed 2025-06-12 | 31.19M shares 10-Q · filed 2025-06-12 | 21.12M shares derived: average of 3 quarters · filed 2025-06-12 | 16.01M shares derived: average of 4 quarters · filed 2025-06-12 |
| 2024-01-31 | 23.20M shares 10-Q · filed 2025-03-10 | 11.95M shares derived: average of 2 quarters · filed 2025-03-10 | 8.20M shares derived: average of 3 quarters · filed 2025-03-10 | 6.33M shares derived: average of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | 708.87K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-19 | 705.10K shares derived: average of 2 quarters · filed 2024-12-19 | 701.56K shares derived: average of 3 quarters · filed 2024-12-19 | 692.61K shares 10-K · filed 2024-12-19 |
| 2023-07-31 | 701.32K shares 10-Q · filed 2024-09-10 | 697.91K shares derived: average of 2 quarters · filed 2024-09-10 | 687.19K shares 10-Q · filed 2024-09-10 | |
| 2023-04-30 | 694.50K shares 10-Q · filed 2024-06-14 | 680.00K shares 10-Q · filed 2024-06-14 | ||
| 2023-01-31 | 651.07K shares 10-Q · filed 2024-03-11 | |||
| 2022-10-31 | 655.15K shares 10-K · filed 2024-01-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |